Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC008 in T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
NCT05532722Phase 2Completed
- Sponsor
- Abcuro
- Start
- Sep 2022
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ulviprubart in T-cell large granular lymphocytic leukemia (T-LGLL), sponsored by Abcuro. Started Sep 2022; status: completed.
02
Drugs
ulviprubart
03
Conditions
T-cell large granular lymphocytic leukemia (T-LGLL)
Beyond the preview
Go deeper on NCT05532722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532722.